Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Clinical Trial ID NCT01822509

PubWeight™ 14.40^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01822509

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Ipilimumab for Patients with Relapse after Allogeneic Transplantation.	N Engl J Med	2016	1.88
2	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.	Oncoimmunology	2014	1.22
3	The targeting of immunosuppressive mechanisms in hematological malignancies.	Leukemia	2014	1.18
4	Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".	Toxins (Basel)	2014	0.92
5	Novel immunotherapies for hematologic malignancies.	Immunol Rev	2015	0.90
6	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.	Bone Marrow Transplant	2015	0.89
7	Targeting the innate immune system as immunotherapy for acute myeloid leukemia.	Front Oncol	2015	0.89
8	New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.	Clin Cancer Res	2014	0.83
9	Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).	Ther Adv Hematol	2016	0.79
10	Immune Mechanisms in Myelodysplastic Syndrome.	Int J Mol Sci	2016	0.78
11	Immunotherapy strategies for multiple myeloma: the present and the future.	Immunotherapy	2013	0.76
12	Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.	Biol Blood Marrow Transplant	2015	0.76
13	Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.	J Natl Cancer Inst	2015	0.75
14	Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.	J Mol Med (Berl)	2015	0.75
15	Novel therapeutic options in Acute Myeloid Leukemia.	Leuk Res Rep	2016	0.75
16	Immunomodulatory drugs II: Immune Checkpoint Agents in Acute Leukemia.	Curr Drug Targets	2015	0.75